OBR Daily Commentary

forumImage

Imfinzi Significantly Improves Overall Survival In The Phase III PACIFIC Trial For Unresectable Stage III Non-small Cell Lung Cancer

(AstraZeneca) May 25, 2018 - Imfinzi met the second primary endpoint of overall survival which was both statistically-significant and clinically-meaningful at a planned interim analysis.

Read Article arrow

H. Jack West, MD (Posted: May 25, 2018)

quotes

This finding of a significant OS result was as I would have expected -- with the profound and sustained PFS benefit going out to at least 18 months, as well as a significant benefit with consolidation durvalumab in time to new metastatic disease or death, it was nearly inconceivable that there wouldn't be a significant improvement in OS. What remains to be seen, however, is whether this will be a sustained OS benefit that actually raises the tail of the curve and leads to more patients alive and without disease at 3 and 4 and more years, or whether the year of durvalumab is just delaying the relapse that would otherwise occur in the same proportion of people. In other words, can immunotherapy eradicate the residual disease in people who would otherwise be destined to relapse and die of their cancer, leading to more cures, or is it merely suppressing the disease that will still lead to relapse, just now with enough of a time delay to lead to a transient improvement in survival.

We await not only the data leading to this press release, but also the more longitudinal results of this important trial.

quotes

Reply

Add Comment 1 Comment(s)

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...